Clinical consensus on respiratory syncytial virus (RSV) infection prophylaxis and the use of palivizumab in paediatric cardiology;Consenso clínico sobre la profilaxis de la infección por virus respiratorio sincitial y el uso del palivizumab en cardiología pediátrica

Anales de Pediatria

Volumn 72, Issue 6, 2010, Pages

  López, C Medrano ^a   Garcia Guereta L ^b   Pineda, L Fernández ^c   Concepción, P Malo ^d   Álvaro, E Maroto ^a   De Soto, J Santos ^e   Casero, J Lirio ^f   Cabrera, P Suárez ^g   Martínez, F Caballero ^h  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^g HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^h Molecular Neuro Oncogenetics Laboratory   (Spain)

Author keywords

Consensus; Paediatric cardiology; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

HEALTH SURVEY; HUMAN; INFECTION PREVENTION; MEDICAL SOCIETY; MEDICAL SPECIALIST; NONHUMAN; PEDIATRIC CARDIOLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS INFECTION; REVIEW; VIRUS INFECTION;

EID: 77953231953     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2010.03.001     Document Type: Article

References (60)

1. J. Figueras, J. Lpez, C. Medrano, R. Bermdez-Caete, L. Fernndez, and P.A. Bonillo Consenso multidisciplinar espaol sobre la profilaxis de la infeccin respiratoria peditrica por virus respiratorio sincitial An Pediatr (Barc) 69 2008 63 71
2. M.H. Beers Explicit criteria for determining potentially inappropriate medication use by the elderly Arch Intern Med 157 1997 1531 1536
3. N.C. Dalkey The Delphi Method: An experimental study of group opinion 1969 Rand Corporation Santa Monica (California) Publication RM-59999 PR
4. N. Dalkey, B. Brown, and S. Cochran The Delphi method, III: Use of self ratings to improve group estimates 1969 Rand Corporation Santa Monica (California) Publication RM-6115-PR
5. S. Peir, and E. Portella El grupo nominal en el entorno sanitario. Quaderns de Salut Publica i Administraci de Serveis de Salut 1 2003 Escola Valenciana d'Estudis per a la Salut Valencia
6. L.A. Goodman Snowball sampling Ann Math Statist 32 1961 148 170
7. E.A. Holey, J.L. Feeley, J. Dixon, and V.J. Whittaker An exploration of the use of simple statistics to measure consensus and stability in Delphi studies BMC Med Res Methodol 7 2007 52
8. D.M. Fick, J.W. Cooper, W.E. Wade, J.L. Waller, J.R. Maclean, and M.H. Beers Updating the beers criteria for potentially inappropriate medication use in older adults. Results of a US consensus panel of experts Arch Intern Med 163 2003 2716 2724
9. P. Royle, and N. Waugh Literature searching for clinical and costeffectiveness studies used in health technology assessments reports carried out for the National Institute for Clinical Excellence appraisal system Health Technol Assess 7 2003 1 51
10. Centre for Evidence-Based Medicine [homepage on the Internet]. Levels of evidence 2001259788537. 259788537EHEditor Hispanium259788537AQ: Por favor, indquenos la fecha de visita a la pgina web.Disponible en: http://www.cebm.net/
11. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis Diagnosis and management of bronchiolitis Pediatrics 118 2006 1774 1793
12. C.E. Behrendt, M.K. Decker, D.J. Burch, P.H. Watson International RSV Study Group International variation in the management of infants hospitalized with respiratory syncytial virus Eur J Pediatr 157 1998 215 220
13. B.L.P. Bloemeres, A.M. Van Furth, M.E. Weijerman, R.J.B. Gemke, C.J.M. Broers, and K. Van den Ende Down syndrome: A novel risk factor for respiratory syncytial virus bronchiolitis. A prospective birth-cohort study Pediatrics 120 2007 1076 1081
14. A. Bonillo Perales, J. Dez-Delgado Rubio, A. Ortega Montes, P. Infante Mrquez, M.R. Jimnez Liria, J. Batlles Garrido Comparacin con el Impact-RSV Study Group Antecedentes perinatales y hospitalizacin por bronquiolitis An Esp Pediatr 53 2000 527 532
15. T.G. Boyce, B.G. Mellen, E.F. Mitchel, P.F. Wright, and M.R. Griffin Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid J Pediatr 137 2000 865 870
16. Bustos Lozano G, De la Cruz Brtolo J, Farfn Sedano FJ. Recomendaciones de inmunoprofilaxis del virus respiratorio sincitial con palivizumab. Efectividad de Medicamentos en Neonatologa. Madrid: Direccin General de Farmacia y Productos Sanitarios (Consejera de Sanidad y Consumo. Comunidad de Madrid); 2004.
17. X. Carbonell-Estrany, J. Quero IRIS Study Group Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons Pediatr Infect Dis J 20 2001 874 879
18. S. Chvez-Bueno, A. Mejas, and R.C. Welliver Respiratory syncytial virus bronchiolitis. Current and future strategies for treatment and prophylaxis Treat Respir Med 5 2006 483 494
19. S. Chiroli, F. Macagno, and C. Lucioni Cost-efficacy analysis of palivizumab in the prevention of respiratory syncytial virus infections in young children with hemodynamically significant congenital heart disease Ital J Pediatr 31 2005 188 194
20. Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcase E, Zerr DM. Variation in inpatient diagnostic testing and management of bronchiolitis. Pediatrics. 115:8783.
21. G. Cilla, A. Sarasua, M. Montes, N. Arostegui, D. Vicente, and E. Prez-Yarza Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain Epidemiol Infect 134 2006 506 513
22. S.A. Cohen, R. Zanni, A. Cohen, M. Harrington, P. Vanveldhuisen, M.L. Boron for the Palivizumab Outcomes Registry Group Palivizumab use in subjects with congenital heart disease: Results from the 20002004 palivizumab outcomes registry Pediatr Cardiol 29 2008 382 387
23. A. Duppenthaler, R.A. Ammann, M. Gorgievski-Hrisoho, J.P. Pfammatter, and C. Aebi Low Incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease Arch Dis Child 89 2004 961 965
24. N.O. Elhassan, M.E. Sorbero, C.B. Hall, T.P. Stevens, and A.W. Dick Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease Arch Pediar Adolesc Med 160 2006 1070 1076
25. C.M. El Saleeby, G.W. Somes, J.P. DeVincenzo, and A.H. Gaur Risk factors for severe respiratory syncytial virus Disease in Children with cancer: the importance of lymphopenia and young age Pediatrics 121 2008 235 243
26. T.F. Feltes, A.K. Cabalka, H.C. Meissner, F.M. Piazza, D.A. Carlin, F.H. Top for the Cardiac Synagis Study Group Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significat congenital heart disease J Pediatr 143 2003 532 540
27. J. Figueras Aloy, X. Carbonell-Estrany, J. Quero para el Iris Study Group Estudio de casos y controles de los factores de riesgo relacionados con la infeccin por el virus respiratorio sincitial que precisa hospitalizacin en nios prematuros de 3335 semanas de edad gestacional en Espaa Pediatr Infect Dis J 23 2004 815 820
28. J. Figueras Aloy, J. Quero el Comit de Estndares de la Sociedad Espaola de Neonatologa Recomendaciones para la prevencin de la infeccin por virus respiratorio sincitial An Pediatr (Barc) 63 2005 357 362
29. M. Grimaldi, B. Gouyon, F. Michaut, F. Huet, and J.B. Gouyon Burgundy Perinatal Network. Severe respiratory syncytial virus bronchiolitis: Epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia Pediatr Infect Dis J 23 2004 1081 1085
30. E. Henckel, J. Luthander, E. Berggren, H. Kapadia, L. Naver, and M. Norman Palivizumab propylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population Pediatr Infect Dis J 23 2004 27 31
31. S. Joffe, G.T. Ray, G.J. Escobar, S.B. Black, and T.A. Lieu Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants Pediatrics 104 1999 419 427 (Pubitemid 29424659)
32. T. Lacaze-Masmonteil, J.C. Roz, and B. Fauroux French Pediatricians' Group of Sunagis Patients' Name-Based Programs. Incidence of respiratory syncytial virus related hospitalizations in high-risk children Pediatr Pulmonol 34 2002 181 188
33. T. Lacaze-Masmonteil, P. Truffert, D. Pinquier, P. Daoud, G. Goldfarb, and E. Vicaut Lower respiratory tract illness and RSV prophylaxis in veri premature infants Arch Dis Child 89 2004 562 567
34. B.J. Law, J.M. Langley, U. Allen, B. Paes, D.S.C. Lee, and Ian Mitchell The Pediatric Investigators Collaborative Network on Infections in Canada Study of predictors of hospitalization for respiratory syncitial virus Pediatr Infect Dis 23 2004 806 814
35. P. Lzaro de Mercado, J. Figueras Aloy, E. Domnech Martnez, I. Echniz Urcelay, R. Closa Monasterolo, and M.A. Wood Wood La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infeccin por virus respiratorio sincitial en prematuros de 3235 semanas en Espaa An Pediatr (Barc) 65 2006 316 324
36. C. Medrano, L. Garca-Guereta, J. Grueso, B. Insa, F. Ballesteros, J. Casaldaliga CIVIC Study Group from the Spanish Society of Pediatric Cardiology and Congenital Heart Disease Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: The CIVIC Epidemiologic Study Cardiol Young 17 2007 360 371
37. C. Medrano Lpez, and L. Garca-Guereta Silva Infecciones respiratorias y cardiopatas congnitas: dos estaciones del estudio CIVIC An Pediatr (Barc) 67 2007 329 336
38. C. Medrano Lpez, L. Garca-Guereta Silva, J. Lirio Casero, J. Garca Prez en representacin del Grupo CIVIC, Grupo de Trabajo de Infecciones de la Sociedad Espaola de Cardiologa Peditrica y Cardiopatas Congnitas Infecciones respiratorias, Sndrome de Down y cardiopatas congnitas: estudio CIVIC 21 An Pediatr (Barc) 71 2009 38 46
39. M. Nakazawa, T. Saji, F. Ichida, K. Oyama, K. Harada, and S. Kususda Guidelines for the use of palivizumab in infants and young children with congenital heart disease Pediatr Int 48 2006 190 193
40. M.J.C. Nuijten, W. Wittenberg, and M. Lemeier Cost effectiveness of pavilizumab for respiratory syncytial virus prophylaxis in high-risk children Pharmacoeconomics 25 2007 55 71
41. P.I. Oh, K.L. Lanctĵt, A. Yoon, D.S. Lee, B.A. Paes, B.S. Simmons Composs Investigators Palivizumab prophylaxis for respiratory syncytial virus in Canada: Utilization and outcomes. Pediatr Infect Dis J 21 2002 512 518
42. Palivizumab Outcomes Registry Study Group Palivizumab prophylaxis of respiratory syncytial virus disease in 20002001: Results from the Palivizumab Outcomes Registry Pediatr Pulmonol 35 2003 484 489
43. C. Pedraz, X. Carbonell-Estrany, J. Figueras-Aloy, J. Quero and The Iris Study Group Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants Pediatr Infect Dis J 22 2003 823 827
44. E.G. Prez-Yarza, A. Moreno, P. Lzaro, A. Mejas, and O. Ramilo The association between respiratory syncytial virus infection and the development of childhood asthma: A systematic review of the literature Pediatr Infect Dis J 26 2007 733 739
45. D. Prais, T. Schonfeld, and J. Amir Admission to the Intensive Care Unit for respiratory syncytial virus bronchiolitis: A national survey before palivizumab use Pediatrics 112 2003 548 552
46. Respiratory syncytial virus. Red Book Online. 2003:523 [Section 3. Summaries of Infections Diseases.
47. J.S. Sampalis Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants J Pediatr 143 2003 S150 S156
48. Scottish Intercollegiate Guidelines Network. Bronchiolitis in children: A national clinical guideline. 2007. Disponible en: http://www.sing.ac.uk/pdf/ sign91.pdf.
49. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 161:15017.
50. N. Sigurs, P.M. Gustafsson, R. Bjarnason, F. Lundberg, D. Schmidt, and F. Sigurbergsson Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13 Am J Respir Crit Care Med 171 2005 137 141
51. R.L. Smyth, and P.J.M. Openshaw Bronchiolitis. Lancet 368 2006 312 322
52. R.T. Stein, M. Halonen, D. Sherrill, L.M. Taussig, W.J. Morgan, and A.L. Wright Virus respiratorio sincitial en la fase inicial de la vida y riesgo de sibilancias y alergia hasta los 13 aos Lancet 354 1999 541 545
53. Surez Cabrera P, Malo Concepcin P, Maroto E, Santos de Soto J. Recomendaciones para la prevencin de la infeccin por virus respiratorio sincitial en pacientes con cardiopatia congnita. SECPCC. Disponible en: http://www.secardioped.org/pdfs/profilaxis-virus-vrs.pdf
54. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants Pediatrics 102 1998 531 537
55. R. Tulloh, M. Marsh, M. Blackburn, F. Casey, W. Lenney, and P. Weller Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease Cardiol Young 13 2003 420 423
56. E.E.L. Wang, and N.K. Tang Immunoglobulin for preventing respiratory syncytial virus infection Cochrane Database Syst Rev 1999 Art. N° CD001725
57. S. Wegner, J.J. Vann, G. Liu, P. Byrns, C. Cypra, and W. Campbell Direct cost analyses of palivizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program Pediatrics 114 2004 1612 1619
58. C. Almansa, E. Rey, E. Bolaos, M. Palma, A. lvarez, and M. Daz-Rubio Opinin de los mdicos espaoles sobre el sndrome de intestino irritable: resultados de un estudio utilizando el mtodo Delphi Rev Esp Enferm Dig 99 2007 210 217
59. A. Dago, P. Arcos, F. lvarez de Toledo, M.I. Baena, J. Martnez, and I. Gorostiza Indicadores de riesgo de morbilidad prevenible causada por medicamentos Gac Sanit 21 2007 29 36
60. E.A. Holey, J.L. Feeley, J. Dixon, and V.J. Whittaker An exploration of the use of simple statistics to measure consensus and stability in Delphi studies BMC Med Res Methodol 7 2007 52